Immune checkpoint inhibitors (ICIs) often impair the interaction between checkpoint proteins (such as PD-1) and their partner proteins (PD-L1), which allows the T cells to eradicate tumor cells (Havel et al., 2019). Here, CD274 is linked to neoplasm.